Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Alzamend Neuro (ALZN) and Cardiol Therapeutics (CRDL)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Neurogene (NGNE), Alzamend Neuro (ALZN) and Cardiol Therapeutics (CRDL) with bullish sentiments.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neurogene (NGNE)
Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Neurogene on April 2 and set a price target of $180.00. The company’s shares closed last Tuesday at $20.65, close to its 52-week low of $13.47.
According to TipRanks.com, Ijem is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Neurogene with a $86.50 average price target, which is a 322.6% upside from current levels. In a report issued on March 23, LifeSci Capital also maintained a Buy rating on the stock with a $50.00 price target.
See the top stocks recommended by analysts >>
Alzamend Neuro (ALZN)
In a report issued on April 5, Edward Woo from Ascendiant maintained a Buy rating on Alzamend Neuro, with a price target of $25.00. The company’s shares closed last Tuesday at $0.95, close to its 52-week low of $0.64.
According to TipRanks.com, Woo is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Alzamend Neuro has an analyst consensus of Moderate Buy, with a price target consensus of $25.00.
Cardiol Therapeutics (CRDL)
Canaccord Genuity analyst Edward Nash maintained a Buy rating on Cardiol Therapeutics on April 2 and set a price target of $8.00. The company’s shares closed last Tuesday at $1.39.
According to TipRanks.com, Nash is a 5-star analyst with an average return of
Currently, the analyst consensus on Cardiol Therapeutics is a Moderate Buy with an average price target of $8.50, which is a 525.0% upside from current levels. In a report issued on April 2, H.C. Wainwright also reiterated a Buy rating on the stock with a $9.00 price target.
Read More on NGNE:
Disclaimer & DisclosureReport an Issue
- Neurogene price target lowered to $180 from $200 at Canaccord
- Buy Rating Backed by Strong NGN-401 Clinical Progress, De-Risking Efficacy Data, and Solid Cash Runway in Rett Syndrome
- Buy Rating Underpinned by De-Risked NGN‑401 Development, Aligned Manufacturing Strategy, and Cash Runway Through Key 2027–28 Catalysts
- Neurogene Advances Rett Gene Therapy Toward BLA With Strong Cash Runway
- 1 Top Stock to Buy Now with 350% Upside, 3/24/2026, According to Top Analysts
